Neurology
'Counting The Cost of Meningitis' Video shows how a signature can help save lives
September 18, 2011 11:35 pm | by RealWire | News | CommentsMeningitis Awareness Week (19-25th September) sees the launch of an online video to support Meningitis Research Foundation's (MRF) Counting the Cost of Meningitis campaign and builds support for vaccination against meningitis and septicaemia. (meningitis.org/sign)MRF is petitioning the UK...
Jazz Pharmaceuticals Announces Presentation at the UBS Global Life Sciences Conference in New York on September 20
September 16, 2011 4:35 am | by Bio-Medicine.Org | News | CommentsPALO ALTO, Calif., Sept. 16, 2011 /- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today that the company will make a presentation at the UBS Global Life Sciences Conference in New York on Tuesday, September 20, 2011 at 9:30 a.m. Eastern Time. Company management will provide a...
Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
September 13, 2011 9:36 am | by Bio-Medicine.Org | News | CommentsSAN DIEGO, Sept. 13, 2011 /- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the UBS Global Life Sciences Conference in New York. The live presentation takes...
Omeros Unlocks Four Additional Orphan GPCRs
September 13, 2011 4:36 am | by Bio-Medicine.Org | News | CommentsSEATTLE, Sept. 13, 2011 /- Omeros Corporation (NASDAQ: OMER ) today reported that it has identified compounds that interact selectively with each of four additional orphan G protein-coupled receptors (GPCRs) – GPR15, GPR39, GPR78 and GPR161. Omeros has now announced that it has...
Roche Starts Early Stage Clinical Trial in Down Syndrome
September 9, 2011 8:36 am | by Bio-Medicine.Org | News | CommentsBASEL, Switzerland and NUTLEY, N.J., Sept. 9, 2011 /- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of its first Phase 1 clinical trial to investigate the safety and tolerability of a molecule designed to address the cognitive and behavioral deficits associated with...
"Scientific Oktoberfest" Draws the Worldwide Leading Researchers in the Field of Chemical Biology to Munich
September 9, 2011 3:35 am | by Bio-Medicine.Org | News | CommentsMUNICH, September 9, 2011 /- The "Scientific Oktoberfest" will be this year's meeting point for some of the internationally most distinguished researchers in the field of Chemical Biology. The so-called "CIPS M Fest of Chemical Biology" will be held from the 15 th to the 16 th of...
Curemark Issued Patent for the Diagnosis of Parkinson's Disease
September 8, 2011 9:36 am | by Bio-Medicine.Org | News | CommentsRYE, N.Y., Sept. 8, 2011 /- Curemark LLC , a drug research and development company focused on the treatment of neurological diseases, announced today that it was issued Patent 8,012,710: Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders. ...
Life Recovery Systems Awarded Contract With Premier for Patient Temperature Management
September 8, 2011 9:36 am | by Bio-Medicine.Org | News | CommentsKINNELON, N.J., Sept. 8, 2011 /- Life Recovery Systems announced today that it has been awarded a new three-year agreement by Premier Purchasing Partners, LP, the group purchasing unit of the Premier healthcare alliance, that makes the ThermoSuit System available by contract to its more...
NeuroSigma Receives Notice of Award from NIH for an STTR Grant for its Trigeminal Nerve Stimulation Therapy for Epilepsy
September 6, 2011 4:36 am | by Bio-Medicine.Org | News | CommentsLOS ANGELES, Sept. 6, 2011 /- NeuroSigma, Inc., a Los Angeles-based medical device company, today announced it has received a notice of award for an NIH Small Business Technology Transfer (STTR) Phase I grant from the National Institute of Neurological Disorders and Stroke (NINDS)....
Vycor Medical, Inc. Files Restated Financial Statements
September 2, 2011 7:36 am | by Bio-Medicine.Org | News | CommentsBOCA RATON, Fla., Sept. 2, 2011 /- On September 2, 2011, Vycor Medical, Inc. (the "Company") filed the following amended Annual Reports and Quarterly Reports with the Securities and Exchange Commission for the following periods: Form 10-K (1st Amendment) for the fiscal year ended...
Valeant Pharmaceuticals to Present at Industry Conferences
September 2, 2011 4:35 am | by Bio-Medicine.Org | News | CommentsMISSISSAUGA, Ontario, Sept. 2, 2011 /- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) today announced that certain members of its senior management team will be participating at the following conferences: J. Michael Pearson, Chairman and Chief Executive Officer...
Neurocrine Biosciences To Present at the Stifel Nicolaus 2011 Healthcare Conference
September 1, 2011 9:36 am | by Bio-Medicine.Org | News | CommentsSAN DIEGO, Sept. 1, 2011 /- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Stifel Nicolaus 2011 Healthcare Conference in Boston. The live presentation...
BioBDx to Present at the 2011 BioPharm America Conference
August 31, 2011 11:37 am | by Bio-Medicine.Org | News | CommentsPLYMOUTH MEETING, Pa., Aug. 31, 2011 /- BioBDx announced today that the Company's Chairman and CEO Byron Hewett will present at the 2011 BioPharm America Conference taking place September 7-9. BioBDx manufactures and markets the Quotient® System, a tool that objectively...
CoLucid Pharmaceuticals Raises $7.5 Million of Planned $9.5 Million
August 30, 2011 6:35 am | by Bio-Medicine.Org | News | CommentsDURHAM, N.C., Aug. 30, 2011 /PRNewswire-iReach/ -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced today that it has raised $7.5 million of a planned $9.5 million convertible note financing from its existing investors to support further late stage...
Hologram Method Used to Study Neurons
August 25, 2011 8:46 pm | by Massachusetts Institute of Technology | News | CommentsThe approach could ultimately be used to rapidly screen new drugs designed to protect brain cells.
NeuroDyne Medical to be sold to Zynex
August 25, 2011 7:46 am | by Mass High Tech: The Journal of New England Technology | News | CommentsNeuroDyne Medical Corp. of Cambridge has received a letter of intent from Zynex Inc. of Colorado which plans to buy substantially all of the assets of NeuroDyne, for undisclosed terms.
Valeant Pharmaceuticals Completes Acquisition of Sanitas Group
August 19, 2011 6:50 am | by Bio-Medicine.Org | News | CommentsMISSISSAUGA, Ontario, Aug. 19, 2011 /- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) announced that effective August 19, 2011, the company completed its previously announced acquisition of AB Sanitas (NASDAQ OMX: SAN1L). About Valeant Valeant Pharmaceuticals...
Valeant Pharmaceuticals Announces Resignation of Michael Van Every From Valeant's Board of Directors
August 18, 2011 5:48 am | by Bio-Medicine.Org | News | CommentsMISSISSAUGA, Ontario, Aug. 18, 2011 /- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that Michael Van Every has resigned from Valeant's Board of Directors due to health reasons. "We want to thank Michael for his many years of service to the Company, first...
CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
August 18, 2011 5:48 am | by Bio-Medicine.Org | News | CommentsDURHAM, N.C., Aug. 18, 2011 /PRNewswire-iReach/ -- Durham, NC, August 18, 2011 /- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced today that it has received clearance to proceed with clinical studies of lasmiditan (formerly known as COL-144) under IND...
Automakers Test In-Car Brain Sensors
August 17, 2011 8:46 pm | by Massachusetts Institute of Technology | News | CommentsManufacturers are testing a brain-wave-sensing system that sounds an alarm when it detects sleepiness.
Pacing the Heart with Light
August 15, 2011 8:43 pm | by Massachusetts Institute of Technology | News | CommentsA new study uses optogenetics to control beating heart cells, pointing the way toward a better pacemaker.
MDA Collaborates with AVI BioPharma on First Phase 2 Placebo-Controlled Clinical Trial of Exon-51 Skipping Drug as Potential Therapy for Duchenne Muscular Dystrophy
August 15, 2011 6:47 pm | by Bio-Medicine.Org | News | CommentsTUCSON, Ariz., Aug. 15, 2011 /PRNewswire-USNewswire/ -- More than a decade of targeted Muscular Dystrophy Association-funded research, made possible as a result of generous public support of the MDA Labor Day Telethon and thousands of grass-roots special events, has today culminated in...
American Association for Cancer Research Hosts Fourth Annual Science of Cancer Health Disparities Conference
August 15, 2011 8:49 am | by AACR | News | CommentsTweet A UNIQUE AND FOCUSED CONFERENCE TO HIGHLIGHT ADVANCES IN UNDERSERVED POPULATIONS WASHINGTON, D.C., SEPT. 18-21, 2011 What: The Fourth AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved will bring together scientists...
Adeona Reports Second Quarter 2011 Financial Results
August 15, 2011 6:49 am | by Bio-Medicine.Org | News | CommentsANN ARBOR, Mich., Aug. 15, 2011 /- Adeona Pharmaceuticals, Inc. (AMEX: AEN ), a developer of innovative medicines for serious central nervous system diseases, today reported its second quarter 2011 financial results for the period ended June 30, 2011, as well as updates since the...
Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
August 12, 2011 4:44 am | by Bio-Medicine.Org | News | CommentsSAN DIEGO, Aug 12, 2011 /- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today announced that Robert E. Hoffman will rejoin Arena on August 29, 2011, as Vice President, Finance and Chief Financial Officer. Mr. Hoffman served in various financial positions with Arena for over 13 years before...
